A phase III study of futibatinib (TAS-120) versus gemcitabine-cisplatin (gem-cis) chemotherapy as first-line (1L) treatment for patients (pts) with advanced (adv) cholangiocarcinoma (CCA) harboring fibroblast growth factor receptor 2 (FGFR2) gene rearrangements (FOENIX-CCA3)
JOURNAL OF CLINICAL ONCOLOGY. Bd. 38. H. 4. 2020
Erscheinungsjahr: 2020
Publikationstyp: Zeitschriftenaufsatz
| Geprüft | Bibliothek |
Autoren
Borad, Mitesh J. (Autor)
Bridgewater, John A. (Autor)
Morizane, Chigusa (Autor)
Shroff, Rachna T. (Autor)
Oh, Do-Youn (Autor)
Moehler, Markus H. (Autor)
Furuse, Junji (Autor)
Benhadji, Karim A. (Autor)
He, Helen (Autor)
Valle, Juan W. (Autor)
Klassifikation
DDC Sachgruppe:
Medizin
